“Trement Medical”, funded by Guangzhou Trauer Biotechnology Co., LTD (Stock Code: 831187) in April 2016, is a clinical-stage gene therapy company, which develop life-changing gene therapies for severe diseases of the blood system. Our management team has deep expertise and a track record of building exceptional life science companies. Three research centers have already been established: molecular center, cell biology center, and virus production center. We have developed a product engine that may transform treatment for a wide range of diseases, and we have multiple preclinical product programs. Our pipeline includes CCR5-GENE EDITING001 for HIV, which is in an ongoing animal study, as well as preclinical program HBB-GENE EDITING002 for β-thalassemia and sickle cells disease.
“Trement Medical” is committed to advancing the field of CRISPR mediated genome editing by innovating and investing in areas such as target site design and engineering, in vivo programmed nuclease delivery techniques, as well as process development and production.
We have broad strategic collaborations with Chinese Academy of Science, Sun Yat-sen University and Jinan University.